Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats

Journal of Dairy Science

Volumn 93, Issue 7, 2010, Pages 3056-3064

  Marin P ^a   Escudero, E ^a   Fernandez Varon E ^a   Ramirez M J ^a   Carceles C M ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Difloxacin; Lactating goat; Long acting formulation; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DIFLOXACIN; DRUG DERIVATIVE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; FEMALE; GOAT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MILK; SPAIN; STAPHYLOCOCCUS AUREUS; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; FEMALE; GOATS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; MICROBIAL SENSITIVITY TESTS; MILK; SPAIN; STAPHYLOCOCCUS AUREUS;

CAPRA HIRCUS; STAPHYLOCOCCUS AUREUS;

EID: 77953905879     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2010-3257     Document Type: Article

References (53)

1. Abd El-Aty A.M., Goudah A. Some pharmacokinetic parameters of pefloxacin in lactating goats. Vet. Res. Commun. 2002, 26:553-561.
2. Abd El-Aty A.M., Goudah A., Ismail M., Shimoda M. Disposition kinetics of difloxacin in rabbit after intravenous and intramuscular injection of dicural. Vet. Res. Commun. 2005, 29:297-304.
3. Atef M., el-Banna H.A., Abd-El-Aty A.M., Goudah A. Pharmacokinetics of difloxacin in goats. Dtsch. Tierarztl. Wochenschr. 2002, 109:320-323.
4. Atkinson H.C., Begg E. Prediction of drug distribution into human milk from physicochemical characteristics. Clin. Pharmacokinet. 1990, 18:151-167.
5. Bhardwaj R., Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J. Pharm. Sci. 1996, 85:915-919.
6. Boscia J.A., Kobasa W.D., Kaye D. Comparison of difloxacin, enoxacin and cefazolin for the treatment of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 1988, 32:262-264.
7. Brown S.A. Fluoroquinolones in animal health. J. Vet. Pharmacol. Ther. 1996, 19:1-14.
8. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M07-A8 2009, CLSI (Clinical and Laboratory Standards Institute), Clinical and Laboratory Standards Institute, Wayne, PA. 8th ed.
9. Cox S.K. Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: A retrospective analysis. J. Vet. Pharmacol. Ther. 2007, 30:381-386.
10. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 1998, 26:1-10.
11. Ding H.Z., Yang G.X., Huang X.H., Chen Z.L., Zeng Z.L. Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular and oral single-dose applications. J. Vet. Pharmacol. Ther. 2008, 31:200-204.
12. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61:377-392.
13. Elmas M., Tras B., Kaya S., Bas A.L., Yazar E., Yarsan E. Pharmacokinetic of enrofloxacin after intravenous and intramuscular administration in Angora goats. Can. J. Vet. Res. 2001, 65:64-67.
14. Fang W., Pyörälä S. Mastitis-causing Escherichia coli: Serum sensitivity and susceptibility to selected antibacterials in milk. J. Dairy Sci. 1996, 79:76-82.
15. Fernández-Varón E., Cárceles C.M., Marín P., Martos N., Escudero E., Ayala I. Pharmacokinetics of difloxacin after intravenous, intramuscular and intragastric administration to horses. Am. J. Vet. Res. 2006, 67:1076-1081.
16. Fernández-Varón E., Cárceles C.M., Marín P., Vancraeynest D., Montes A., Sotillo J., García-Martínez J.D. Disposition kinetic and pharmacokinetics-pharmacodynamic integration of difloxacin against Staphylococcus aureus isolates from rabbits. Res. Vet. Sci. 2008, 84:90-94.
17. Gehring R., Smith G.W. An overview of factors affecting the disposition of intramammary preparations used to treat bovine mastitis. J. Vet. Pharmacol. Ther. 2006, 29:237-241.
18. Gibaldi M., Perrier P. Pharmacokinetics 1982, Marcel Dekker Inc., New York, NY.
19. Goudah A., Mouneir S.M. Comparative pharmacokinetics of difloxacin in goat kids and lambs. Small Rumin. Res. 2008, 78:186-192.
20. Granneman G.R., Snyder K.M., Shu V.S. Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob. Agents Chemother. 1986, 30:689-693.
21. Johnston T.P., Punjabi M.A., Froelich C. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 1992, 9:425-434.
22. Kalogridou-Vassiliadou D. Mastitis-related pathogens in goat milk. Small Rumin. Res. 1991, 4:203-212.
23. Kempf I., van den Hoven R., Gesbert F., Guittet M. Efficacy of difloxacin in growing broiler chicken for the control of infection due to pathogenic Mycoplasma gallisepticum. J. Vet. Med. B 1998, 45:305-310.
24. Lees P., Shojaee Aliabadi F. Rational dosing of antimicrobial drugs: Animals versus human. Int. J. Antimicrob. Agents 2002, 19:269-284.
25. Lerondelle C., Poutrel B. Characteristics of non-clinical mammary infections. Ann. Rech. Vet. 1984, 15:105-112.
26. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clin. Infect. Dis. 1998, 27:33-39.
27. Marín P., Cárceles C.M., Escudero E., Fernández-Varón E. Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. Can. J. Vet. Res. 2007, 71:74-76.
28. Marín P., Escudero E., Fernández-Varón E., Cárceles C.M. Pharmacokinetics and milk penetration of difloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. J. Vet. Pharmacol. Ther. 2007, 30:74-79.
29. Marín P., Escudero E., Fernández-Varón E., Cárceles C.M. Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous and intramuscular administration to lactating goats. J. Dairy Sci. 2007, 90:4219-4225.
30. Marín P., Fernández-Varón E., Escudero E., Cárceles C.M. Pharmacokinetics after intravenous, subcutaneous and intramuscular administration of difloxacin in sheep. Res. Vet. Sci. 2007, 83:234-238.
31. Mavrogianni V.S., Fthenakis G.C. Efficacy of difloxacin against respiratory infections of lambs. J. Vet. Pharmacol. Ther. 2005, 28:325-328.
32. McManaman J.L., Neville M.C. Mammary physiology and milk secretion. Adv. Drug Deliv. Rev. 2003, 55:629-641.
33. Olchowy T.W.J., TerHune T.N., Herrick R.L. Efficacy of difloxacin in calves experimentally infected with Mannheimia haemolytica. Am. J. Vet. Res. 2000, 61:710-713.
34. Overhoff K.A., McConville J.T., Yang W., Johnston K.P., Peters J.I., Williams R.O. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm. Res. 2008, 25:167-175.
35. Pec E.A., Wout Z., Jhonston T.P. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J. Pharm. Sci. 1996, 81:626-630.
36. Powers J. Statistical analysis of pharmacokinetics data. J. Vet. Pharmacol. Ther. 1990, 13:113-120.
37. Schmolka I.R. Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 1972, 6:571-582.
38. Shojaee Aliabadi F., Lees P. Antibiotic treatment for animals: Effect on bacterial population and dosage regimen optimisation. Int. J. Antimicrob. Agents 2000, 14:307-313.
39. Shumaker R.C. PKCALC: A basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab. Rev. 1986, 17:331-348.
40. Siefert H.M., Kohlsdorfer C., Steinke W., Witt A. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: Tissue distribution in male rats. J. Antimicrob. Chemother. 1999, 43(Suppl. B):61-67.
41. Silva E.R., Siqueira A.P., Martins J.C.D., Ferreira W.P.B., Silva N. Identification and in vitro antimicrobial susceptibility of Staphylococcus species isolated from goat mastitis in the Northeast of Brazil. Small Rumin. Res. 2004, 55:45-49.
42. Stamm J.M., Hanson C.W., Chu D.T., Bailer R., Vojtko C., Fernandes P.B. In vitro evaluation of A-56619 (difloxacin) and A-56620: New aryl-fluoroquinolones. Antimicrob. Agents Chemother. 1986, 29:193-200.
43. Toutain P.L., Bousquet-Mélou A. Bioavailability and its assessment. J. Vet. Pharmacol. Ther. 2004, 27:455-466.
44. Toutain P.L., Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimise dosage regimens in veterinary medicine. J. Vet. Pharmacol. Ther. 2004, 27:467-477.
45. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999, 58:29-36.
46. van den Hoven R., Wagenaar J.A., Walker R.D. In vitro activity of difloxacin against canine bacterial isolates. J. Vet. Diagn. Invest. 2000, 12:218-223.
47. White E.C., Hinckley L.S. Prevalence of mastitis pathogens in goat milk. Small Rumin. Res. 1999, 33:117-121.
48. Wolfson J.S., Hooper D.C. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 1989, 2:378-424.
49. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6:165-175.
50. Yamaoka K., Tamigawara Y., Uno J. A pharmacokinetic analysis program (MULTI) for microcomputers. J. Pharmacobiodyn. 1981, 4:879-885.
51. Yun M., Choi H., Jung J., Kim C. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement. Int. J. Pharm. 1999, 189:137-145.
52. Zhang L., Parsons D.L., Navarre C., Kompella U.B. Development and in vitro evaluation of stained release Poloxamer 407 (P407) gel formulation of ceftiofur. J. Control. Release 2002, 85:73-81.
53. Ziv G. Drug selection and use in mastitis: Systemic vs. local therapy. J. Am. Vet. Med. Assoc. 1980, 176:1109-1115.